Global mRNA Cancer Therapeutics Market Report and Forecast 2024-2032

mRNA Cancer Therapeutics Market Size

The global mRNA cancer therapeutics market was valued at USD 13.23 billion in 2023 driven by the increasing prevalence of cancer across the globe. The market is expected to grow at a CAGR of 14.56% during the forecast period 2024-2032 and attain a market value of USD 32.13 billion by 2032. 

mRNA Cancer Therapeutics Market Outlook

• According to the World Health Organization, around 20 million new cancer cases with 9.7 million deaths were reported in 2022.

• In April 2024, MD Anderson Cancer Center and CureVac N.V. collaborated to manufacture mRNA cancer vaccines. The partnership merges CureVac's antigen discovery and manufacturing with MD Anderson's cancer research skills, targeting critical tumor types.

• In June 2024, CSPC Pharmaceutical Group introduced a new cancer cell therapy using synthetic messenger RNA (mRNA) technology, which has been approved for human clinical trials in China. Such developments are expected to boost the market value for mRNA cancer therapeutics in the forecast period.

mRNA Cancer Therapeutics Market Overview

mRNA cancer therapeutics involves using mRNA technology to guide the body's cells to produce certain proteins that trigger an immune reaction against cancer cells. It is a method of delivery of mRNA sequences containing antigens or therapeutic proteins into patient cells to trigger protein production, helping the immune system recognize and combat cancer. This method enables personalized cancer therapies tailored to an individual's unique cancer mutations.

Messenger RNA (mRNA) is a form of RNA produced from DNA within the nucleus. It acts as a template for protein synthesis. It delivers genetic data to ribosomes in the cytoplasm and is essential in gene expression by guiding the arrangement of amino acids to create proteins necessary for cell activities.

mRNA Cancer Therapeutics Market Growth Drivers

Increased Cancer Incidence Boosts Market Growth

The increase in cancer incidences globally has fueled the expansion of the mRNA cancer therapeutics market. According to the World Health Organization, around 20 million new cancer cases with 9.7 million deaths was reported in 2022 and expected to increase by around 77% by 2050. It is driven by various factors including an aging society, lifestyle modifications, and genetic influences in the population. mRNA therapies provide personalized and precise cancer treatment by assisting cells in generating proteins that fight cancer. This method has sparked funding and studies, as mRNA platforms have the potential to tackle difficult cancer issues. The growing need for advanced treatments, due to the rise in cancer cases, is expanding the market and enhancing patient outcomes.

Rising R&D Initiatives to Meet Rising mRNA Cancer Therapeutics Market Demand

Research and development efforts are driving the global need for mRNA cancer treatments. Innovations in molecular biology enable accurate aim at cancer cells, providing a hopeful substitute for conventional therapies. In May 2024, University of Florida researchers conducted trials of an mRNA cancer vaccine on human patients with glioblastoma. The outcomes were encouraging, mirroring the success seen in pet dogs and preclinical mouse studies. The advancement was made possible by funding and resources from UF Health Cancer Centre, resulting in a Phase 1 trial for paediatric brain cancer. Preclinical models and artificial intelligence in drug discovery expedite the development process. Consequently, an expanding array of mRNA cancer treatments is progressing through trials to meet the rising need for groundbreaking therapies.

mRNA Cancer Therapeutics Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Integration with Artificial Intelligence (AI) and Machine Learning (ML)

The incorporation of AI and ML is revolutionizing the process of drug discovery and development, improving accuracy and productivity. AI algorithms quickly identify mRNA sequences to target cancer cells, accelerating the identification process. ML models forecast how biological systems interact to improve design. AI analytics provide customized treatment plans using patient information, simplifying the process of clinical trials.

High Specificity and Reduced Side Effects

mRNA treatments utilize cells to produce specific proteins, triggering immune responses against cancer while preserving healthy tissue. By tailoring treatments to genetic profiles, they optimize efficacy and reduce side effects. Moreover, they present minimal long-term hazards by breaking down naturally. These advancements are transforming the field of cancer treatment, offering safer and more effective options.

Increased Funding and Collaboration

Significant investments from governments, private investors, and pharmaceutical companies are fueling mRNA technology research in oncology. The funding supports advanced research, clinical trials, and production scaling. Collaborative efforts among biotech firms, academics, and healthcare providers are enhancing knowledge sharing and technology integration. Joint ventures and alliances are pooling resources to expedite mRNA-based cancer treatments to market, overcoming challenges and delivering therapies faster. In April 2024, MD Anderson Cancer Center and CureVac N.V. collaborated to manufacture mRNA cancer vaccines. The partnership merges CureVac's antigen discovery and manufacturing with MD Anderson's cancer research skills, targeting critical tumor types.

Increased Government Regulation

Regulatory agencies are adjusting structures to facilitate the quick advancement and usage of mRNA technologies, tackling special difficulties, and enforcing efficient approval procedures. Governments are offering clear instructions on safety and effectiveness, encouraging teamwork, and supporting openness and effectiveness in clinical trials and market introduction. These improvements are crucial for the progression of mRNA cancer treatments to maintain patient safety.

mRNA Cancer Therapeutics Market Segmentation

Market Breakup by Type of Cancer

• Adeno Carcinomas

• Mucinous Carcinomas

• Adenosquamous Carcinomas

• Others

Market Breakup by End User

• Hospitals & Clinics

• Ambulatory Surgical Centers

• Research Institutes

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

mRNA Cancer Therapeutics Market Share

Market Segmentation Based on Type of Cancer to Witness Substantial Growth

The market breakup based on the type of cancer includes adeno carcinomas, mucinous carcinomas, adenosquamous carcinomas, and others. Among them, adenocarcinomas are expected to dominate the market because of their high incidence in individuals. Adenocarcinomas begin in glandular tissues such as the lungs, prostate, and breast. On the other hand, mucinous carcinoma creates mucus in ovaries, colon, and pancreas which is targeted by mRNA therapies by aiming at specific molecular markers. Adenosquamous carcinomas contains two types of cells, namely, squamous cells and gland-like cells in the cervix and pancreas.

mRNA Cancer Therapeutics Market Breakup Based on End User

Based on the end user, the market is segmented into hospitals and clinics, ambulatory surgical centers, research institutes, and others.

Hospitals and clinics are expected to dominate the market because of their specialized staff, advanced tools, and capacity to offer complete care from diagnosis to aftercare. Their expertise in dealing with complicated cancer cases and managing potential side effects makes them the top pick for patients receiving mRNA therapy, providing essential assistance during the treatment process.

mRNA Cancer Therapeutics Market Analysis by Region

Based on region, the market report covers North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa.

North America is expected to dominate the market with its robust healthcare system, significant research and development funding, and biopharmaceutical industry. Increased cancer prevalence and financial support for clinical trials also contribute to its strong presence in the market. Medical research advancements and collaboration among nations are driving the growth of Europe's market for mRNA cancer therapeutics. European countries with well-developed healthcare systems play an active role in clinical trials and research.

The market in the Asia-Pacific region is rapidly expanding driven by increasing cancer rates, better healthcare infrastructures, and higher investments in biotechnology. China and Japan are at the forefront of embracing innovative treatments and carrying out medical studies to address the need for individualized cancer therapies. For instance, in June 2024, CSPC Pharmaceutical Group introduced a new cancer cell therapy using synthetic messenger RNA (mRNA) technology, which has been approved for human clinical trials in China.

Leading Players in the mRNA Cancer Therapeutics Market

The key features of the market report include patent analysis, grant analysis, funding, and investment analysis as well as strategic initiatives including recent partnerships and collaborations by the leading players. The major companies in the market are as follows:

Moderna, Inc.

Moderna Inc (Moderna) is a biotechnology company that focuses on the development of messenger RNA (mRNA) therapeutics and vaccines. The company develops and discovers drugs that produce proteins or antibodies inside patient cells. It was established in 2010 and has its headquarters in Massachusetts, United States. Moderna  was established to utilize mRNA to develop treatments for diseases swiftly and efficiently. Over the years, the company has pioneered mRNA medicine, advanced various pipelines and showing clinical promise in cancer, rare diseases, and infectious disease vaccines.

BioNTech SE

BioNTech SE is a German biotech company focusing on creating immunotherapies for cancer and infectious diseases. Research is being done on mRNA therapeutics, gene therapies, antibodies, and small molecule immunomodulators for cancer treatment. It was founded in the year 2008. The company is also assessing potential treatments for HIV, tuberculosis, malaria, hepatitis B, influenza, and COVID-19. It utilizes FixVac  and iNeST technology platforms for the exploration and creation of cancer immunotherapies that focus on antigens and neoantigens.

CureVac SE 

CureVac, a multinational biotech company established in 2000, specializes in mRNA technology for medical applications. It has introduced key technologies for mRNA vaccines against COVID-19 and is expanding into new therapeutic areas. In April 2024, CureVac N.V. and MD Anderson collaborated to manufacture mRNA cancer vaccines.

Cipla Limited 

Cipla Ltd was established in 1935 and is based in Mumbai, India. The company manufactures and distributes branded medicines, generics, and APIs in various therapeutic areas. It also operates in consumer healthcare and biosimilars. In June 2024, Cipla announced an additional EUR 3 million investment in Ethris GmbH to enhance its presence in the mRNA space by delivering mRNAs directly to the respiratory system.

Other players in the market include Argos Therapeutics, Inc., AstraZeneca Plc, Ethris GmbH, GSK Plc, RNAimmune, Inc., and Sanofi S.A., among others.

Key Highlights of the Report

Key Questions Answered in the mRNA Cancer Therapeutics Market Report

• What was the global mRNA cancer therapeutics market value be in 2023? 
• What is the global mRNA cancer therapeutics market forecast outlook for 2024-2032? 
• What are the regional markets covered in the EMR report?
• What is market segmentation based on type of cancer? 
• What is market segmentation based on end user? 
• What are the major factors aiding the global mRNA cancer therapeutics market demand? 
• How has the market performed so far and how is it anticipated to perform in the coming years? 
• What are the major drivers, opportunities, and restraints in the market?  
• What are the major trends influencing the market?  
• Which regional market is expected to dominate the market share in the forecast period?  
• Which country is likely to experience elevated growth during the forecast period?  
• Who are the key players involved in the global mRNA cancer therapeutics market? 
• What are the current unmet needs and challenges in the market? 
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?